ASX Announcements

Response to Appendix 4C Query
Appendix 4C - quarterly
Appendix 4G
Annual Report to shareholders
Neuren receives $1 million R&D Tax Incentive
Investor presentation, 3 April 2017
Full Year Statutory Accounts
Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
Trading Halt
S&P DJ Indices Announces March Quarterly Rebalance